Holen Sie sich die Stockscreener-App
3.69
13.38%
-0.57
Vorhandelsmarkt:
3.69
Schlusskurs vom Vortag:
$4.26
Offen:
$3.71
24-Stunden-Volumen:
375.58K
Relative Volume:
2.78
Marktkapitalisierung:
$1.31B
Einnahmen:
$842.96M
Nettoeinkommen (Verlust:
$-185.63M
KGV:
-7.0165
EPS:
-0.5259
Netto-Cashflow:
$-228.52M
1W Leistung:
-10.44%
1M Leistung:
-1.86%
6M Leistung:
-10.65%
1J Leistung:
-21.49%
1-Tages-Spanne:
$3.64
$3.74
1-Wochen-Bereich:
$3.64
$4.36
52-Wochen-Spanne:
$2.84
$5.6405
Evotec Se Adr Stock (EVO) Company Profile
Vergleichen Sie EVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.69 | 1.46B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
147.37 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.53 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.31 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.12 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-08-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-04-04 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-01-07 | Fortgesetzt | Citigroup | Neutral |
Alle ansehen
Evotec Se Adr Aktie (EVO) Neueste Nachrichten
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com
8 New 4-Star Stocks - Morningstar
Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister
Evotec SE (EVO) Stock Forecasts - Yahoo Finance
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria
Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Stock Information - Evotec
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com Australia
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks
Evotec: Management Streamlines Strategy to Refocus on Core Strengths Amid Biologics Momentum - Morningstar
Antibody Discovery Market Size to Achieve USD 22,570 Mn by 2034 | Statifacts - GlobeNewswire Inc.
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - BNN Bloomberg
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Halozyme Therapeutics stock sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Annual General Meeting - Evotec
Investor Relations - Evotec
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Healthcare Sector - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com India
Evotec: Still A Speculative Buy After A Significant Decline (NASDAQ:EVO) - Seeking Alpha
Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders - Center for Biosimilars
Evotec SE ADR earnings, Revenue miss in Q3 By Investing.com - Investing.com India
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Together for Medicines That MatterEvotec - Evotec
Evotec and Biogen Idec in research agreement - Proactive financial news
Finanzdaten der Evotec Se Adr-Aktie (EVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):